Citations with the tag: MYLAN Pharmaceuticals Inc

Results 51 - 100

  • Depakote ER goes generic.
     // Pharmaceutical Representative; Apr2009, Vol. 39 Issue 4, p10 

    The article reports on the marketing approval attained by Wockhardt USA and Mylan Pharmaceuticals Inc. for Depakote ER. It mentions that the two pharmaceutical companies will have their 180 days in marketing the newly FDA-approved medication. Moreover, this drug is intended to cure and alleviate...

  • THIS MONTH'S HIGHLIGHTS.
     // PharmaWatch: CNS; Aug2008, Vol. 7 Issue 8, p2 

    The article offers news briefs related to pharmaceutical industry in the U.S. Eli Lilly & Co. has announced that the Food and Drug Administration (FDA) has approved Cymbalta for the management of fibromyalgia. Mylan Pharmaceuticals Inc. has also received the final approval from the FDA for its...

  • News Focus.
     // Pharmaceutical Representative; Aug2005, Vol. 35 Issue 8, p10 

    Reports developments in the pharmaceutical industry in the U.S. Plan of Wyeth Pharmaceuticals to reduce its primary care and women's health sales force; Implementation of the restructuring plan by Wyeth through a regional pilot program; Decision of Mylan Laboratories to close its Mylan Bertek...

  • Merck claims Mylan infringement.
     // Medical Marketing & Media; Apr99, Vol. 34 Issue 4, p28 

    Reports on the patent infringement lawsuit filed by Merck against Mylan Pharmaceuticals Inc.

  • Pharma: Other News To Note.
     // BioWorld Today; 5/20/2013, Vol. 24 Issue 96, p7 

    This section offers news briefs in the U.S. pharmaceutical industry as of May 20, 2013 including Bristol-Myers Squibb Co.'s plan to voluntary delist its two dollars convertible preferred stock from the New York Stock Exchange, the distribution of the Fenofibrate Tablets from Mylan...

  • new products.
     // Dermatology Times; Jan2010, Vol. 31 Issue 1, p64 

    The article evaluates several medical products including the generic acne tx from Mylan Pharmaceuticals Inc., Lipsovir drug for cold sores treament from Medivir AB, and TNS ceramide skin treatment cream from SkinMedica Inc.

  • COMPANY SPOTLIGHT - Mylan Laboratories.
     // PharmaWatch: CNS; Jul2008, Vol. 7 Issue 7, p17 

    The article presents a company profile of the U.S.-based pharmaceutical firm Mylan Laboratories Inc. (Mylan). Mylan has three principal subsidiaries including Mylan Pharmaceuticals Inc. (MPI), UDL Laboratories Inc. (UDL) and Mylan Technologies Inc. (Mylan Tech), each having their own respective...

  • CNS News Round-Up.
     // PharmaWatch: CNS; Dec2008, Vol. 7 Issue 12, p2 

    The article offers world news briefs related to the pharmaceutical industry. The Mylan Pharmaceuticals Inc. has received final approval to market its levetiracetam tablets in 250 milligram (mg), 500 mg and 750 mg formulations. AstraZeneca PLC has announced approval of Seroquel XR and Seroquel...

  • REPORTERS Notebook.
     // Drug Store News; 11/12/2007, Vol. 29 Issue 14, p22 

    The article offers news briefs related to the pharmaceutical industry in the U.S. Mylan and its subsidiary, Mylan Pharmaceuticals Inc., have signed a marketing agreement with Glaxo-SmithKline for paroxetine hydrochloride extended-release tablets. Merck KgaA has decided to halt its research and...

  • DERMATOLOGICAL DISORDERS.
     // MPR - Pharmacist's Edition; Fall2013, Vol. 7 Issue 3, p49 

    The article offers brief information on several dermatological agents for acne treatment including the Aczone from Allergan Pharmaceuticals Inc., the Amnesteem from Mylan Pharmaceuticals Inc. and the Benzac AC from Galderma SA.

  • New products.
    STEIN, JULIANNE // Drug Topics; Oct2013, Vol. 157 Issue 10, p49 

    The article offers brief information on several over-the-counter (OTC) drugs including the Astagraf XL from Astellas Pharma US Inc., the nitroglycerin lingual spray from Perrigo Co. and the bupropion HCI extended-release (ER) tablets USP from Mylan Pharmaceuticals Inc.

  • Mylan signs settlement agreement with Wyeth for depression drug.
    STEIN, JULIANNE // PharmaWatch: CNS; Jan2010, Vol. 9 Issue 1, p10 

    The article reports that Mylan Pharmaceuticals Inc. has entered into settlement and licensing agreements with Wyeth regarding the venlafaxine hydrochloride extended release capsules. The capsules are the generic version of Wyeth's Effexor XR capsules, a treatment for major depressive disorder....

  • Pharma: Other News To Note.
    STEIN, JULIANNE // BioWorld Today; 6/11/2012, Vol. 23 Issue 112, p8 

    The article reports on the settlement of a dispute of Mylan Pharmaceuticals Inc. with Teva Pharmaceuticals USA Inc. in line with the suit filed by Mylan against the U.S. Food and Drug Administration (FDA) related to its abbreviated new drug application for Modafinil tablets.

  • DERMATOLOGICAL DISORDERS.
    STEIN, JULIANNE // Monthly Prescribing Reference; Dec2009, Vol. 25 Issue 12, p114 

    The article offers information on several drugs for the treatment of dermatological disorders and discusses their indications, contraindications and precautions. Aczone from Allergan Inc. is a topical treatment for acne vulgaris and should be applied twice daily. Amnesteem from Mylan...

  • Mylan wins FDA approval for additional strengths of antipsychotic drug.
    STEIN, JULIANNE // PharmaWatch: CNS; Sep2009, Vol. 8 Issue 9, p20 

    The article reports that U.S. Food and Drug Administration (FDA) approved the abbreviated new drug application (ANDA) for haloperidol tablets of the Mylan Pharmaceuticals Inc. It mentions that the approval of the haloperidol tablets adds strength to the Mylan's marketed haloperidol in various...

  • DERMATOLOGICAL DISORDERS.
    STEIN, JULIANNE // Monthly Prescribing Reference; Oct2009, Vol. 25 Issue 10, p106 

    The article offers information about pharmaceuticals used in treating dermatological disorders. It discusses the indications, precautions, interactions, adverse reactions, and supply of these drugs. They include retinoid Amnesteem from Mylan Pharmaceuticals Inc. for severe recalcitrant nodular...

  • Mylan receives 'approvable letter' for apomorphine.
    STEIN, JULIANNE // PharmaWatch: CNS; August 2003, Vol. 2 Issue 8, p6 

    Reports on the acquirement of an approval by Bertek Pharmaceuticals Inc. for its apomorphine hydrochloride injection in the U.S. Submission of additional information by the firm to the Food and Drug Administration; Use of the drug in Parkinson's disease; Administration of the drug.

  • Mylan's ANDA for generic multiple sclerosis drug accepted for filing by FDA.
    STEIN, JULIANNE // PharmaWatch: CNS; Nov2009, Vol. 8 Issue 11, p4 

    The article reports that Mylan Pharmaceutical Inc.'s abbreviated new drug application (ANDA) has been accepted for filing by the Food and Drug Administration in the U.S. The product called glatiramer acetate injection is a generic version of Teva's Copaxone, a product indicated for the treatment...

  • Pharma & Fine Chemicals: Market Briefs.
    STEIN, JULIANNE // Chemical Market Reporter; 01/24/2000, Vol. 257 Issue 4, p12 

    Provides news briefs on pharmaceutical and fine chemical industry as of January 24, 2000. Marketing agreement between Mylan Laboratories Inc. and Bertek Pharmaceuticals Inc.; Approval for Tequin quinolone antibiotic from Bristol-Myers Squibb Co.; Human clinical trial for polyglutamate...

  • Teva files lawsuit against Mylan and Natco Pharma for Copaxone.
    STEIN, JULIANNE // PharmaWatch: CNS; Dec2009, Vol. 8 Issue 12, p4 

    The article reports on the filing of a lawsuit by Teva Pharmaceuticals Industries in the U.S. District Court of New York against Mylan Pharmaceuticals, Mylan Inc. and Natco Pharma for patent infringement of Copaxone in the U.S. It states that the lawsuit has been filed within the 45-day period...

  • Mylan to Launch New Branded Drug for Parkinson's Disease.
    Mirasol, Feliza // Chemical Market Reporter; 5/10/2004, Vol. 265 Issue 19, p12 

    Reports on the U.S. Food and Drug Administration's (FDA) approval of Mylan Laboratories Inc.'s drug for Parkinson's disease, Apokyn or apormorphine HC1 for injection. Launching and distributions plans of the company for the drug; Mylan's strengthening of its branded drugs business through its...

  • Mylan Pharmaceuticals.
    Mirasol, Feliza // Drug Store News; 7/23/2001, Vol. 23 Issue 9, p44 

    Introduces Mylan Pharmaceuticals Incorporated's brand of buspirone hydrochloride tablets, an alternative to Bristol-Myers Squibb's BuSpar. Mechanics of its dosing flexibility; Advantage of the Mylan drug.

  • New York to receive $18 million in settlement with four drug companies.
    Reinhardt, Eric // Business Journal (Central New York); 10/23/2009, Vol. 23 Issue 43, p22 

    The article reports that four drug companies will pay the New York state an amount of more than 18 million dollars as a settlement in multistate Medicaid fraud. According to Attorney General Andrew Cumo four companies including Mylan Pharmaceuticals Inc., UDL Laboratories Inc, and AstraZeneca...

  • REPORTER'S NOTEBOOK.
    Reinhardt, Eric // Drug Store News; 8/23/2004, Vol. 26 Issue 10, p53 

    Reports on developments in the pharmaceutical industry for the period ended August 23, 2004. U.S. Food and Drug Administration's approval of Pfizer's Lipitor (atorvastatin) as a supplement in reducing the risk of heart attacks; Abbott Laboratories' submission of a new drug application for...

  • DERMATOLOGICAL DISORDERS.
    Reinhardt, Eric // MPR - Pharmacist's Edition; Fall2015, Vol. 9 Issue 3, p42 

    The article presents information on several drugs for treating dermatological disorders. For every drug, the details related to its target users, adverse reactions, generic availability status, mode of supply, contraindications, interactions, and the pharmaceutical company manufacturing or...

  • HITTING THE HEADLINES: BRIC Retains Pharma Investments.
    Reinhardt, Eric // Pharmaceutical Technology Europe; Sep2012, Vol. 24 Issue 9, p10 

    The article reports that emerging countries continue to attract the pharmaceutical firms in Brazil, Russia, India and China (BRIC). It says that a recent poll in PharmTech.com revealed that 36% chosen Brazil as one of the countries most interested in expanding business operations, followed by...

  • Bertek: Apokyn to make small moves in market.
    Reinhardt, Eric // PharmaWatch: CNS; June 2004, Vol. 3 Issue 6, p4 

    Reports on the approval of the U.S. Food and Drug Administration to Apokyn as the first Parkinson's disease immobility treatment. Role of Bertek Pharmaceuticals Inc. in the marketing of Apokyn; Definition of Parkinson's disease; Benefits of the drug marketing for Bertek.

  • Growing and Giving Back.
    Kasey, Pam // State Journal (WV); 6/1/2012, Vol. 28 Issue 22, p1 

    The article reports on the contributions of pharmaceutical company Mylan Pharmaceuticals Inc. in Morgantown, West Virginia on the state's economy. It states that the company has created 3,000 jobs of the total private non-farm employment of nearly 40,000 in Monongalia County. Ken Busz of...

  • More Must Be Done to Help Bioscience Companies Grow.
    Gregg, Derek // State Journal (WV); 3/11/2011, Vol. 27 Issue 10, p21 

    The article reports on the emerging of bioscience industry in West Virginia. According to BIO, the industry trade organization, the industry involves research and development of advance health care, environmental, agricultural, and industrial products. Also included are various biosciences...

  • High court won't revisit public-figure issue.
    Gregg, Derek // Hollywood Reporter; 10/3/95, Vol. 339 Issue 12, p6 

    Reports that the United States Supreme Court has rejected a request to consider American Cyanamid as a public figure in the lawsuit against Mylan Pharmaceuticals.

  • New Products Hit the Market.
    Gregg, Derek // Chain Drug Review; 5/21/2012, Vol. 34 Issue 9, p70 

    The article informs about the launch of several drugs in the U.S. including doxycycline hyclate delayed-release tablets by Mylan Pharmaceuticals Inc., olanzapine tablets by Dr. Reddy's Laboratories Ltd., dexlansoprazole capsules by Par Pharmaceutical Inc.

  • Endo Pharmaceuticals files lawsuit against Mylan.
    Gregg, Derek // PharmaWatch: CNS; Oct2011, Vol. 10 Issue 10, p23 

    The article reports on the lawsuit filed by Endo Pharmaceuticals Inc. against Mylan Pharmaceuticals Inc. in connection with the filing of an abbreviated new drug application (ANDA).

  • Pfizer: Lipitor wins a new indication.
    Gregg, Derek // PharmaWatch: Monthly Review; Nov2005, Vol. 4 Issue 11, p16 

    The article reports that the U.S. Food and Drug Administration (FDA) has granted approval for Mylan Pharmaceuticals Inc. to market a generic version of Pfizer Inc.'s drug, Norvasc. As Mylan is the first to file for generic approval to market a generic version of Norvasc in the U.S., the company...

  • Pfizer: the pressure is on for Norvasc.
    Gregg, Derek // PharmaWatch: Monthly Review; Nov2005, Vol. 4 Issue 11, p17 

    The article reports that Mylan Pharmaceuticals Inc. has received the approval from the U.S. Food and Drug Administration (FDA) to market a generic version of Pfizer Inc.'s blockbuster blood pressure drug Norvasc. As Mylan is the first to file for generic approval to market a generic version of...

  • CNS News Round-Up.
    Gregg, Derek // PharmaWatch: Monthly Review; Dec2008, Vol. 7 Issue 12, p12 

    The article offers world news briefs related to pharmaceutical industry. Belgian biotechnology company UCB has told that the U.S. Food and Drug Administration has approved its new antiepileptic, Vimpat, for use as an add-on therapy in patients aged 17 and older. Mylan Pharmaceuticals has also...

  • New products.
    Gregg, Derek // Drug Topics; Jul2011, Vol. 155 Issue 7, p56 

    The article offers brief information on several medications including Horizant Extended-Release tablets from GlaxoSmithKline, oxycodone from Mylan Pharmaceuticals Inc., and Arbinoxa from Hawthorn Pharmaceuticals Inc.

  • Suncrest Towne Centre Successful Hub for Eclectic Business Mix.
    BONNSTETTER, CATHY // State Journal (WV); 9/11/2015, Vol. 31 Issue 36, p15 

    No abstract available.

  • Importer of Controlled Substances; Notice Of Registration; Mylan Pharmaceuticals, Inc.
    Rannazzisi, Joseph T. // Federal Register; 5/22/2012, Vol. 77 Issue 99, p30326 

    The article presents information on an application filed by Mylan Pharmaceuticals Inc. to the U.S. Drug Enforcement Administration to register it as an importer of the controlled substances including amphetamine, methadone and morphine.

  • Mylan wins FDA approval for generic Risperdal tablets.
    Rannazzisi, Joseph T. // PharmaWatch: CNS; Nov2008, Vol. 7 Issue 11, p12 

    The article focuses on the approval received by Mylan Pharmaceuticals Inc., a subsidiary of Mylan Inc., from the U.S. Food and Drug Administration for its abbreviated new drug application of risperidone tablets USP, 0.25mg, 0.5mg, 1mg, 2mg, 3mg and 4mg. It pertains that risperidone tablets are...

  • Depression Update.
    Rannazzisi, Joseph T. // PharmaWatch: CNS; Jan2009, Vol. 8 Issue 1, p9 

    The article offers depression related developments worldwide. The Food and Drug Administration (FDA) approved Mylan Pharmaceuticals Inc.'s abbreviated new Drug Application for veniafaxine hydrochloride. The FDA approved Watson Laboratories Inc.'s abbreviated New Drug Application for bupropion...

  • product showcase.
    Rannazzisi, Joseph T. // Pharmacy Today; Jun2012, Vol. 18 Issue 6, p36 

    The article offers information related to approval of medicine. The U.S. Food and Drug Administration (FDA) announced the approval of avanafil, a phosphodiesterase type 5 (PDE5) inhibitor for erectile dysfunction in men. UCB Inc. announced that FDA approved the formulation of rotigotine...

  • CNS News Round-Up.
    Rannazzisi, Joseph T. // PharmaWatch: Monthly Review; Aug2008, Vol. 7 Issue 8, p13 

    The article offers updates on the approval of drugs for diseases related to central nervous system in the U.S. Eli Lily and Co. announced the approval of its Cymbalta for the management of fibromyalgia by the Food and Drug Administration (FDA). Mylan Pharmaceuticals Inc. received final approval...

  • The Industry.
    Rannazzisi, Joseph T. // Pharmaceutical Representative; Oct2010, Vol. 40 Issue 10, p7 

    The article offers news briefs related to pharmaceutical industries in the U.S. Kevin Kruse was appointed as the new executive director of the Society of Pharmaceutical and Biotech Trainers (SPBT). Bristol-Myers Squibb Co. has agreed to take on the biopharma company ZymoGenetics Inc. which hopes...

  • OTHER NEWS TO NOTE.
    Rannazzisi, Joseph T. // BioWorld Today; 10/8/2007, Vol. 18 Issue 195, p2 

    This section offers news briefs on the pharmaceutical industry in the U.S. as of October 2007. Genzyme Corp. gained approval to market Elaprase in Japan for the treatment of Hunter syndrome. The Memphis Bioworks Foundation has launched an accelerator seed fund seeking to encourage development of...

  • Clinical Trials News.
    Rannazzisi, Joseph T. // Applied Clinical Trials; Jun2004, Vol. 13 Issue 6, p18 

    This article presents news briefs related to the pharmaceutical industry in the U.S. Research Triangle Park, North Carolina-based GlaxoSmithKline PLC has received the U.S. Federal Drug Administration (FDA) approval for a 25-mg children's dosage of GERD drug Zantac, ranitidine hydrochloride...

  • Depression Update.
    Rannazzisi, Joseph T. // PharmaWatch: CNS; Jul2008, Vol. 7 Issue 7, p10 

    The article provides updates concerning drug developments for depression. Sanofi-Aventis SA reported favorable results from a new study of its Ambien CR CIV tablets. Meanwhile, AstraZeneca PLC has applied for the approval of the Seroquel XR extended-release tablet for the treatment of major...

  • Mylan's Alphapharm wins patent litigation on generic Razadyne tablets.
    Rannazzisi, Joseph T. // PharmaWatch: CNS; Oct2008, Vol. 7 Issue 10, p6 

    The article reports on the patent litigation decision in favor of Mylan Pharmaceutical Inc.'s subsidiary Alphapharm regarding USP galantamine tablets in Delaware on August 27, 2008. The U.S. District Court of Delaware invalidated the sole orange book patent asserted against Alphapharm by Janssen...

  • Mylan wins FDA approval for generic Keppra.
    Rannazzisi, Joseph T. // PharmaWatch: CNS; Dec2008, Vol. 7 Issue 12, p8 

    The article reports on the approval by the U.S. Food and Drug Administration on Mylan Pharmaceuticals Inc.'s abbreviated new drug application for levetiracetam tablets, 250, 500 and 750 milligram (mg), which is the generic version of UCB Pharma Inc.'s Keppra. It relates that pursuant to the...

  • SECTION 4: DERMATOLOGICAL DISORDERS.
    Rannazzisi, Joseph T. // Monthly Prescribing Reference; Mar2010, Vol. 26 Issue 3, p100 

    The article provides information on several drugs which are intended for the treatment of dermatological disorders. These drugs include Acanya from Arcutis Pharmaceuticals and Coria Laboratories, Aczone from Allergan, and Amnesteem from Mylan Pharmaceuticals. It also indicates the drugs'...

  • Licensing Update.
    Rannazzisi, Joseph T. // PharmaWatch: Biotechnology; Jul2008, Vol. 7 Issue 7, p16 

    The article provides updates on the licensing agreements among biotechnology companies. Noxxon Pharma AG has signed a licensing agreement with Eli Lilly and Co. regarding the discovery and development of Spiegelmers for the treatment of migraine. Debiopharm Group Co. agreed with its long-term...

Previous 50 Results Next 50 Results
Share

Other Topics